Physician profile
Brooke E Adams
NPI 1154865210
$3,481.12
in general payments reported to CMS, 2019-2025
20 companies · $526 in 2025
The $526 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,253 · 2022: $689 · 2023: $474 · 2024: $539 · 2025: $526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,538.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,115.42 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $520.43 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $371.38 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $335.24 | 2021-2025 | |
| Lilly USA, LLC | $262.73 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Exact Sciences Corporation | $158.17 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Abbvie INC. | $155.82 | 2021-2023 | Ubrelvy |
| Amgen INC. | $138.99 | 2021-2025 | Otezla, Repatha, Repatha |
| Amarin Pharma, INC. | $108.98 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $88.13 | 2021-2023 | Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $48.73 | 2022-2025 | |
| Kowa Pharmaceuticals America, INC. | $41.41 | 2021 | |
| Axsome Therapeutics, INC. | $24.84 | 2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $21.00 | 2021 | |
| Abbott Laboratories | $16.07 | 2023 | Freestyle Libre 3 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $15.56 | 2021 | |
| Phathom Pharmaceuticals, INC. | $15.09 | 2025 | Voquezna |
| Verona Pharma, INC. | $14.83 | 2025 | Ohtuvayre |
| Biohaven Pharmaceuticals, INC. | $14.75 | 2021 | |
| Merck Sharp & Dohme LLC | $13.55 | 2025 | Gardasil 9, Capvaxive |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.